Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?

Besarab, A

Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO? [electronic resource] - ASAIO journal (American Society for Artificial Internal Organs : 1992) - 11-8 p. digital

Publication Type: Journal Article; Review

1058-2916


Anemia--drug therapy
Centers for Medicare and Medicaid Services, U.S.
Drug Administration Schedule
Drug Costs
Erythropoietin--administration & dosage
Hemodialysis Units, Hospital--economics
Humans
Kidney Failure, Chronic--complications
Medicare--economics
Recombinant Proteins--administration & dosage
Reimbursement Mechanisms
Renal Dialysis--economics
United States
United States Food and Drug Administration